Literature DB >> 9103502

Suppression of mammalian K+ channel family by ebastine.

C M Ko1, I Ducic, J Fan, Y M Shuba, M Morad.   

Abstract

Nonsedating H1 receptor (H1-R) antagonists exert variable effects on QT interval, most likely mediated through modulation of cardiac K+ channels. We examined the effects of a novel H1-R antagonist, ebastine, on a family of K+ currents in isolated rat and guinea pig ventricular cardiomyocytes as well as on HERG-induced rapidly delayed rectifier K+ current (I(Kr)) in Xenopus laevis oocytes. The effect of ebastine was compared with that of two other H1-R antagonists, terfenadine and loratadine, with and without reported cardiotoxicity, respectively. In guinea pig ventricular myocytes, ebastine at concentrations approximating those found in plasma under certain conditions suppressed in a voltage-independent manner the I(Kr) (Kd = 0.14 microM, maximum block 74%) more effectively than the slowly delayed rectifier K+ current (I(Ks)) (Kd = 0.8 microM, maximum block 60%). Ebastine also suppressed I(Kr) in HERG-expressing X. laevis oocytes with the Kd value of 0.3 microM and a maximal block of 46% at 3 microM. The block of the rapidly activating delayed rectifier channel in rat myocytes (Iped) (Kd = 1.7 microM, maximum block 58%) had a small voltage dependence. Ebastine only minimally suppressed rat transient K+ current (Ito) (Kd = 1.1 microM, maximum block 10%). The drug was also not a very potent blocker of the inwardly rectifier K+ current (I(K1)) of rat and guinea pig (15 +/- 3% block at 3 microM). At concentrations of <100 nM, ebastine produced negligible effect on all K+ currents. We conclude that ebastine blocks various cardiac K+ channels with different potencies. The group of delayed rectifier K+ currents appeared to be most susceptible to ebastine with the order of sensitivity of I(Kr) > I(Ks) > Iped. Ebastine-induced inhibition of all K+ current types was always weaker than that observed with similar concentrations of terfenadine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103502

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Assessing the cardiac safety of ebastine. Epilogue.

Authors:  D J Roberts
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

Review 2.  Blockade of cardiac potassium and other channels by antihistamines.

Authors:  E Delpón; C Valenzuela; J Tamargo
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

3.  Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format.

Authors:  Sampada A Shahane; Ruili Huang; David Gerhold; Ulrich Baxa; Christopher P Austin; Menghang Xia
Journal:  J Biomol Screen       Date:  2013-09-03

Review 4.  Ebastine: an update of its use in allergic disorders.

Authors:  M Hurst; C M Spencer
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 5.  Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.

Authors:  M Malik; A J Camm
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine.

Authors:  T Kosoglou; M Salfi; J M Lim; V K Batra; M N Cayen; M B Affrime
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

7.  Acute effects of oestrogen on the guinea pig and human IKr channels and drug-induced prolongation of cardiac repolarization.

Authors:  Junko Kurokawa; Masaji Tamagawa; Nobuhiro Harada; Shin-Ichiro Honda; Chang-Xi Bai; Haruaki Nakaya; Tetsushi Furukawa
Journal:  J Physiol       Date:  2008-04-25       Impact factor: 5.182

8.  Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation.

Authors:  David J Diller; Doug W Hobbs
Journal:  J Comput Aided Mol Des       Date:  2007-06-05       Impact factor: 4.179

Review 9.  Safety of antihistamines in children.

Authors:  A P Ten Eick; J L Blumer; M D Reed
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

10.  Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines.

Authors:  S Rico; Rm Antonijoan; Mj Barbanoj
Journal:  J Asthma Allergy       Date:  2009-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.